Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTN4QDT)

• DTT Name: Opioid receptor (OPR)
• Synonyms: Opioid receptor
• Gene Name: OPR
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T23547

Molecular Interaction Atlas (MIA) of This DTT

11 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dextropropoxyphene	DM23HCX	Pain	MG30-MG3Z	Approved	[2]
Ketobemidone	DMM3L6Z	Pain	MG30-MG3Z	Approved	[3]
Levorphanol	DMGS80V	Pain	MG30-MG3Z	Approved	[4]
Methadone	DMTW6IU	Advanced cancer	2A00-2F9Z	Approved	[1]
Nalmefene	DM4YWCZ	Opioid dependence	6C43.2Z	Approved	[5]
Naltrexone	DMUL45H	Alcohol dependence	6C40.2	Approved	[6]
Oxymorphone	DM65AGJ	Pain	MG30-MG3Z	Approved	[7]
Pentazocine	DM1XBHS	Pain	MG30-MG3Z	Approved	[8]
Sufentanil	DMU7YEL	Analgesia	MB40.8	Approved	[9]
Tilidine	DMJW0VS	Pain	MG30-MG3Z	Approved	[10]
Dihydrocodeine	DMB0FWL	Allergic rhinitis	CA08.0	Phase 4	[11]

13 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALO-02	DMKLBHX	Pain	MG30-MG3Z	Phase 3	[12]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[13]
AeroLEF	DMNO7BC	Pain	MG30-MG3Z	Phase 2	[14]
AZD-7268	DMC48SP	Anxiety disorder	6B00-6B0Z	Phase 2	[15]
CNSB-001	DM2PEU5	Neuropathic pain	8E43.0	Phase 2	[16]
JKB-122	DMARQ0H	Hepatitis virus infection	1E50-1E51	Phase 2	[17]
NP-2	DMLMZ6Q	Influenza A virus infection	1E30	Phase 2	[18]
OCFENTANIL	DM8TDBY	Pain	MG30-MG3Z	Phase 2	[19]
Odelepran	DMK0MJP	Alcohol dependence	6C40.2	Phase 2	[20]
Oxytrex	DMC3PJS	Pain	MG30-MG3Z	Phase 2	[21]
S-297995	DM26IH8	Opioid dependence	6C43.2Z	Phase 2	[22]
PTI-202	DMNO91Q	Pain	MG30-MG3Z	Phase 1	[23]
SYN-1001	DMX05W8	Pain	MG30-MG3Z	Phase 1	[24]

10 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propiram fumarate	DMW9H7M	Cancer related pain	MG30	Discontinued in Phase 3	[25]
CereCRIB	DMG62H1	Pain	MG30-MG3Z	Discontinued in Phase 2	[26]
OxycoDex	DMHFOIX	Pain	MG30-MG3Z	Discontinued in Phase 2	[27]
PTI-701	DMGO2AV	Pain	MG30-MG3Z	Discontinued in Phase 2	[28]
Ultramorph	DMRDXYV	Pain	MG30-MG3Z	Discontinued in Phase 2	[29]
BL-1827	DMJWLBU	Cancer related pain	MG30	Discontinued in Phase 1	[30]
APF-580	DMYD04O	Pain	MG30-MG3Z	Terminated	[32]
EK-399	DMIP8NB	Inflammation	1A00-CA43.1	Terminated	[33]
Org-30035	DMMA92L	Psychotic disorder	6A20-6A25	Terminated	[34]
OX-23	DMESWV1	Pain	MG30-MG3Z	Terminated	[35]

1 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CB-01-16	DMKFAG3	Constipation	DD91.1	Preclinical	[31]

2 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BRIFENTANIL	DM2JPX7	Pain	MG30-MG3Z	Investigative	[36]
Cyprodine	DM7T96M	Parkinson disease	8A00.0	Investigative	[37]

References

• [1] Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
• [2] Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
• [3] The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
• [4] Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
• [5] Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
• [6] An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
• [8] Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
• [9] mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
• [10] Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
• [11] Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.
• [12] Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain. 2005 Jun;6(6):392-9.
• [13] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [14] Current Research on Opioid Receptor Function. Curr Drug Targets. 2012 February; 13(2): 230-246.
• [15] EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
• [16] Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
• [17] WO patent application no. 2011,1401,90, Tetrazolones as inhibitors of fatty acid synthase.
• [18] Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem. 2001 Jun 1;276(22):18688-94.
• [19] Comparison of ocfentanil and fentanyl as supplements to general anesthesia. Anesth Analg. 1991 Nov;73(5):622-6.
• [20] A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb;38(2):511-20.
• [21] Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83.
• [22] Clinical pipeline report, company report or official report of Shionogi (2011).
• [23] Clinical pipeline report, company report or official report of Pain Therapeutics, Inc.
• [24] Improved brain uptake and pharmacological activity profile of morphine-6-glucuronide using a peptide vector-mediated strategy. J Pharmacol Exp Ther. 2005 May;313(2):712-9.
• [25] The relative analgesic efficacy of propiram fumarate, codeine, aspirin, and placebo in post-impaction dental pain. J Clin Pharmacol. 1984 Jan;24(1):35-42.
• [26] US patent application no. 5,874,099, Methods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix core.
• [27] Differential activation of the -opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model. Br J Pharmacol. 2013 Jan;168(2):375-88.
• [28] Clinical pipeline report, company report or official report of Pain Therapeutics.
• [29] Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 2000 Feb;84(2-3):121-31.
• [30] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013581)
• [31] Clinical pipeline report, company report or official report of Cosmo.
• [32] WO patent application no. 2010,0094,51, Long-acting injectable analgesic formulations for animals.
• [33] Evaluation of the discriminative stimulus effect of an enkephalin analog, EK-399, in the rat. Nihon Yakurigaku Zasshi. 1991 Jun;97(6):361-9.
• [34] WO patent application no. 2010,0332,07, Polymer conjugates of therapeutic peptides.
• [35] CA patent application no. 212323, Method for improving gastrointestinal motility.
• [36] Synthesis and pharmacological evaluation of a series of new 3-methyl-1,4-disubstituted-piperidine analgesics. J Med Chem. 1990 Oct;33(10):2876-82.
• [37] Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.